An observational study in Atopic Dermatitis, sponsored by Prof. Dr. Stephan Weidinger. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Prof. Dr. Stephan Weidinger · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Dermatitis, Atopic with a site in Germany — 19 open to participants now, 42 under way, 9 of them phase 3. Dermatitis, Atopic · Germany.
Among the 230 studies in Dermatitis, Atopic with a site in Germany, this one is the 21st largest by enrollment of the 21 observational ones that give a count, is one of 13 that started in 2022, is one of 21 observational ones, and was the 162nd registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →19 of the 230 studies in Dermatitis, Atopic with a site in Germany are open now. Recruiting first, the newest first:
Apollo Therapeutics Ltd · Sites in Germany, United States, Bulgaria and 5 more countries
Ages 18–65
Chong Kun Dang Pharmaceutical · Sites in Germany, United Kingdom
Ages 18–55 · Healthy volunteers
Pfizer · Sites in Germany, United States, Bulgaria and 6 more countries
Ages 18–64
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Galderma R&D · Sites in Germany, United States, United Kingdom
Ages 12+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 86 · Phase 3 66 · Phase 4 11
First in 1998; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 150 across 283 observational studies indexed under Dermatitis, Atopic.
Median enrollment 195 across the 205 interventional studies, 634 across the 21 observational. Of the 184 that completed or were terminated, 95 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
195 of 230 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. Stephan Weidinger is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Prof. Dr. Stephan Weidinger has 3 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
15 of the studies in Dermatitis, Atopic with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT07230860Janssen Research & Development, LLCA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | 2026-11-19 |
| NCT05099315Charite University, Berlin, GermanyMicrobiome in Atopic Dermatitis Under Systemic Therapy | 2026-12-31 |
| NCT03057860Technische Universität DresdenTREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 230 studies in Dermatitis, Atopic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.
Open-label, non-randomized, single-arm, 12-weeks observational clinical and translational study
Adult patients (n=20) with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare. The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare (n=20). The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
Other: No Intervention
Non Interventional
Change in transepidermal water loss (TEWL) at one non-lesional and one lesional marker skin area at week 2 and week 12 compared to baseline/week 0 (day 0).
To determine the mean change of TEWL in g/m2/h at one non-lesional and one lesional marker skin site at week 2 and week 12 compared to baseline
Time frame: 12 Weeks
Number of epidermal barrier-related genes/pathways differentially expressed in a marker lesional skin site at week 2 and week 12 compared to baseline
To compare the expression of epidermal barrier-related genes at the transcriptome level at a marker lesional skin site at week 2 and week 12 to baseline and to non-lesional skin
Time frame: 12 Weeks
Epidermal thickness and epidermal differentiation markers in a marker lesional skin site at week 2 and week 12 compared to baseline
To compare epidermal thickness (in µm) and the percentage of marker-positive cells (KRT 16, Ki67, FLG) in a marker skin site with reference to the number of cells in the basal layer at week 2 and 12 to baseline and to non-lesional skin
Time frame: 12 Weeks
Stratum corneum biomarker (cytokine) levels (pg/μg protein) in marker skin sites at week 2 and week 12 compared to baseline
To compare stratum corneum biomarker (cytokine) levels (pg/μg protein) in a marker lesional skin site at week 2 and week 12 compared to baseline and to non-lesional skin
Time frame: 12 Weeks
Composition of Bacterial Taxa of one lesional and non-lesional marker skin area at week 2 and week 12 compared to baseline
To identify changes in community composition and diversity at one lesional and one non-lesional marker skin site at week 2 and week 12 as compared to baseline using Next Generation Sequencing techniques
Time frame: 12 Weeks
Transcriptional profile of the keratinocytes in one lesional marker skin area at week 2 and 12 compared to baseline
To compare the transcriptional profile of keratinocytes at one lesional marker skin area at week 2 and 12 compared to baseline and to non-lesional skin using single cell sequencing techniques
Time frame: 12 Weeks
Plan to share: No
Ran from Sep 2022 to primary completion in Dec 2024, 27 months.
Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's 27 months is below that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. Stephan Weidinger